Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FINANCIAL SERVICES FORUM via THE WALTER GROUP
2026 · second_quarter · Q2
Clarity Act
FINANCIAL SERVICES FORUM via THE WALTER GROUP
2026 · second_quarter · RR
Source: Senate LDA
| BRESNAN COMMUNICATIONS |
| 19 |
| 2006–2010 |
| RESEARCH IN MOTION | 17 | 2009–2013 |
| SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) | 17 | 2009–2013 |
| AMERICAN OPTOMETRIC ASSOCIATION | 13 | 2010–2013 |
| MOU PARTNERS | 12 | 2007–2010 |
| REGIONS FINANCIAL CORP. | 12 | 2010–2013 |
| AMGEN USA, INC. | 11 | 2010–2012 |
| CABLEVISION SYSTEMS CORPORATION | 11 | 2011–2013 |
| TIME WARNER CABLE | 11 | 2011–2013 |
| COMCAST CORPORATION | 9 | 2011–2013 |
| AIG (AMERICAN INTERNATIONAL GROUP) | 8 | 2006–2008 |
| RENENCO GROUP | 8 | 2010–2012 |
| FREDDIE MAC | 6 | 2006–2008 |
| HUAWEI TECH. INVESTMENT COMPANY, LTD. | 5 | 2011–2012 |
| AMERICAN ASSOC. OF PEOPLE WITH DISABILITIES | 4 | 2012 |
| ENDOMETRIOSIS FOUNDATION OF AMERICA | 4 | 2026 |
| US EDUCATION FUNDING GROUP | 4 | 2006–2007 |
| ALLIANCE ONE, INC | 3 | 2012–2013 |
| ENG GLOBAL SERVICES | 3 | 2006–2008 |
| PEPSICO | 3 | 2006–2007 |
| PRUDENTIAL FINANCIAL | 3 | 2006–2007 |
| RECORDING INDUSTRY ASSOCIATION OF AMERICA | 3 | 2006–2007 |
| SYNTROLEUM | 3 | 2006–2008 |
| TALENTBRIDGE | 3 | 2026 |
| COLON CANCER ALLIANCE | 2 | 2007 |
| FINANCIAL SERVICES FORUM | 2 | 2026 |
| PARENTS ANONYMOUS | 2 | 2007 |
| ROCHE DIAGNOSTICS CORPORATION | 2 | 2007 |
| WALTER GROUP | 2 | 2008 |
| REGSION'S BANK | 1 | 2008 |
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Pharmaceutical Quality, Security, and Accountability Act
Client: AMERISOURCEBERGEN · Firm: THE WALTER GROUP
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Clarity Act
TALENTBRIDGE via THE WALTER GROUP
2026 · second_quarter · Q2
Employment retention credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDOMETRIOSIS FOUNDATION OF AMERICA via THE WALTER GROUP
2026 · second_quarter · Q2
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDOMETRIOSIS FOUNDATION OF AMERICA via THE WALTER GROUP
2026 · first_quarter · 1A
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TALENTBRIDGE via THE WALTER GROUP
2026 · first_quarter · Q1
Employment retention credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDOMETRIOSIS FOUNDATION OF AMERICA via THE WALTER GROUP
2026 · first_quarter · Q1
HR 6682 Endometriosis Care Act Research, education, awareness and funding for endometriosis.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TALENTBRIDGE via THE WALTER GROUP
2026 · first_quarter · RR
Covid Era ERC tax credit
ENDOMETRIOSIS FOUNDATION OF AMERICA via THE WALTER GROUP
2026 · first_quarter · RR
Raising awareness for endo with education and funding for research and enducation
AMERISOURCEBERGEN via THE WALTER GROUP
2016 · second_quarter · 2T
Repeal of LIFO (last-in, first-out).
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
AMERISOURCEBERGEN via THE WALTER GROUP
2016 · first_quarter · Q1
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
AMERISOURCEBERGEN via THE WALTER GROUP
2015 · fourth_quarter · Q4
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Repeal of LIFO (last-in, first-out).
AMERISOURCEBERGEN via THE WALTER GROUP
2015 · third_quarter · Q3
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Repeal of LIFO (last-in, first-out).
AMERISOURCEBERGEN via THE WALTER GROUP
2015 · second_quarter · Q2
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
AMERISOURCEBERGEN via THE WALTER GROUP
2015 · first_quarter · Q1
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
AMERISOURCEBERGEN via THE WALTER GROUP
2014 · fourth_quarter · Q4
Repeal of LIFO (last in, first out).
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
AMERISOURCEBERGEN via THE WALTER GROUP
2014 · third_quarter · Q3
Repeal of LIFO (last in, first out).
HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
AMERISOURCEBERGEN via THE WALTER GROUP
2014 · second_quarter · Q2
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
JPMORGAN CHASE & CO via THE WALTER GROUP
2014 · second_quarter · 2T
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2014 · first_quarter · 1A
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2014 · first_quarter · Q1
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
JPMORGAN CHASE & CO via THE WALTER GROUP
2014 · first_quarter · Q1
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2013 · fourth_quarter · Q4
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2013 · fourth_quarter · Q4
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
Repeal of LIFO (last in, first out).
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
AMERISOURCEBERGEN via THE WALTER GROUP
2013 · third_quarter · Q3
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2013 · third_quarter · Q3
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2013 · second_quarter · Q2
Prompt pay
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL CABLE TELEVISION ASSOCIATION via THE WALTER GROUP
2013 · second_quarter · 2T
Telecommunications, tax and bonus depreciation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABLEVISION SYSTEMS CORPORATION via THE WALTER GROUP
2013 · second_quarter · 2T
General tax issues Bonus depreciation Anti-trust issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2013 · second_quarter · Q2
Dodd Frank General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2013 · second_quarter · Q2
Medicare doc fix
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIME WARNER CABLE via THE WALTER GROUP
2013 · second_quarter · 2T
General telecom and tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) via THE WALTER GROUP
2013 · second_quarter · 2T
General tax issues Dodd Frank
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH IN MOTION via THE WALTER GROUP
2013 · second_quarter · 2T
General telecom issues Patents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGIONS FINANCIAL CORP via THE WALTER GROUP
2013 · second_quarter · 2T
Dodd Frank
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKHEED MARTIN via THE WALTER GROUP
2013 · second_quarter · 2T
Defense appropriations and general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DME CORPORATION via THE WALTER GROUP
2013 · second_quarter · 2T
Defense appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMCAST CORPORATION via THE WALTER GROUP
2013 · second_quarter · 2T
Cyber security General tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF CATASTROPHE ADJUSTERS via THE WALTER GROUP
2013 · first_quarter · 1T
General labor issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE ONE, INC via THE WALTER GROUP
2013 · second_quarter · 2T
Export of tobacco products under US law
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2013 · second_quarter · Q2
Medicare prompt pay discount exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufactures average sales price.
Filing targets: SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2013 · second_quarter · Q2
General healthcare issues as related to the Optometric Assn.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2013 · second_quarter · Q2
Dodd Frank implementation and tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE ONE, INC via THE WALTER GROUP
2013 · first_quarter · Q1
Export of tobacco products under US law
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMCAST CORPORATION via THE WALTER GROUP
2013 · first_quarter · Q1
cyber security general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABLEVISION SYSTEMS CORPORATION via THE WALTER GROUP
2013 · first_quarter · Q1
general tax issues bonus depreciation anti-trust issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIME WARNER CABLE via THE WALTER GROUP
2013 · first_quarter · Q1
general telecom and tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGIONS FINANCIAL CORP via THE WALTER GROUP
2013 · first_quarter · Q1
Dodd Frank
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2013 · first_quarter · Q1
Medicare doc fix
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) via THE WALTER GROUP
2013 · first_quarter · Q1
general tax issues Dodd Frank
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH IN MOTION via THE WALTER GROUP
2013 · first_quarter · Q1
general telecom issues patents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2013 · first_quarter · Q1
Prompt pay
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2013 · first_quarter · Q1
Dodd Frank general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF CATASTROPHE ADJUSTERS via THE WALTER GROUP
2013 · first_quarter · Q1
General labor isues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL CABLE TELEVISION ASSOCIATION via THE WALTER GROUP
2013 · first_quarter · Q1
Telecommunications, tax and bonus depreciation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKHEED MARTIN via THE WALTER GROUP
2013 · first_quarter · Q1
Defense appropriations and general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DME CORPORATION via THE WALTER GROUP
2013 · first_quarter · Q1
Defense appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE ONE, INC via THE WALTER GROUP
2012 · third_quarter · RR
Trade of company's tobacco products
ASSOCIATION OF CATASTROPHE ADJUSTERS via THE WALTER GROUP
2012 · fourth_quarter · Q4
General labor issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMCAST CORPORATION via THE WALTER GROUP
2012 · fourth_quarter · 4A
bonus depreciation cyber security general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGIONS FINANCIAL CORP via THE WALTER GROUP
2012 · fourth_quarter · 4A
Dodd Frank implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABLEVISION SYSTEMS CORPORATION via THE WALTER GROUP
2012 · fourth_quarter · Q4
Sandy Relief bill general tax issues bonus depreciation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIME WARNER CABLE via THE WALTER GROUP
2012 · fourth_quarter · Q4
S. 2008 - Next Generation Television marketplace act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC via THE WALTER GROUP
2012 · fourth_quarter · 4T
General trade issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2012 · fourth_quarter · Q4
Medicare scope of practice Veteran's Healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) via THE WALTER GROUP
2012 · fourth_quarter · Q4
Dodd Frank implementation general tax and derivative issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH IN MOTION via THE WALTER GROUP
2012 · fourth_quarter · Q4
Cyber security Spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2012 · fourth_quarter · Q4
Dodd Frank implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL CABLE TELEVISION ASSOCIATION via THE WALTER GROUP
2012 · fourth_quarter · Q4
Bonus depreciation Broad ban regulation Universal service fund
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DME CORPORATION via THE WALTER GROUP
2012 · fourth_quarter · Q4
Transportation appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2012 · fourth_quarter · Q4
Medicare reimbursement LIFO Prompt pay
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKHEED MARTIN via THE WALTER GROUP
2012 · fourth_quarter · Q4
National Defense Authorization Act Bonus depreciation
bonus depreciation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSOC. OF PEOPLE WITH DISABILITIES via THE WALTER GROUP
2012 · third_quarter · 3T
ADA issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMCAST CORPORATION via THE WALTER GROUP
2012 · third_quarter · Q3
cyber security Spectrum Co
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABLEVISION SYSTEMS CORPORATION via THE WALTER GROUP
2012 · third_quarter · Q3
program carriage issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIME WARNER CABLE via THE WALTER GROUP
2012 · third_quarter · Q3
program carriage regulation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC via THE WALTER GROUP
2012 · third_quarter · Q3
foreign market access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGIONS FINANCIAL CORP via THE WALTER GROUP
2012 · third_quarter · Q3
Dodd Frank impementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2012 · third_quarter · Q3
scope of practice Veterans eye care Medicare doc fix vision as an essential health benefit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) via THE WALTER GROUP
2012 · third_quarter · Q3
Dodd Frank implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH IN MOTION via THE WALTER GROUP
2012 · third_quarter · Q3
patents cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2012 · third_quarter · Q3
drug shortages Tax, LIFO Medicare part B payments S 733
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE & CO via THE WALTER GROUP
2012 · third_quarter · Q3
Dodd Frank implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF CATASTROPHE ADJUSTERS via THE WALTER GROUP
2012 · third_quarter · Q3
labor issues, overtime compensation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL CABLE TELEVISION ASSOCIATION via THE WALTER GROUP
2012 · third_quarter · Q3
Tax issues, cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DME CORPORATION via THE WALTER GROUP
2012 · third_quarter · Q3
Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKHEED MARTIN via THE WALTER GROUP
2012 · third_quarter · Q3
F-35 and general tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RENENCO GROUP via THE WALTER GROUP
2012 · second_quarter · 2A
General Peruvian trade issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUAWEI TECH. INVESTMENT COMPANY, LTD. via THE WALTER GROUP
2012 · third_quarter · 3T
Foreign trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSOC. OF PEOPLE WITH DISABILITIES via THE WALTER GROUP
2012 · second_quarter · Q2
ADA related issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUAWEI TECH. INVESTMENT COMPANY, LTD. via THE WALTER GROUP
2012 · second_quarter · Q2
HPSCI investigation cyber-security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMCAST CORPORATION via THE WALTER GROUP
2012 · second_quarter · Q2
telecom, taxes and spectrum code, bonus depreciation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CABLEVISION SYSTEMS CORPORATION via THE WALTER GROUP
2012 · second_quarter · Q2
Program carriage issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC via THE WALTER GROUP
2012 · second_quarter · Q2
Foreign market access issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGIONS FINANCIAL CORP via THE WALTER GROUP
2012 · second_quarter · Q2
Dodd-Frank implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OPTOMETRIC ASSOCIATION via THE WALTER GROUP
2012 · second_quarter · Q2
Local coverage determination MLR calculations VA opthalmology service
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURITIES INDUSTRY AND FINANCIAL MARKETS ASSN (SIFMA) via THE WALTER GROUP
2012 · second_quarter · Q2
Dodd Frank implementation tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH IN MOTION via THE WALTER GROUP
2012 · second_quarter · Q2
Cyber security and general telecom issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERISOURCEBERGEN via THE WALTER GROUP
2012 · second_quarter · Q2
Prompt pay, S.733 Gray market drug reform Tax LIFO PDUFA Drug shortages
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DME CORPORATION via THE WALTER GROUP
2012 · second_quarter · Q2
Transportation appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
Repeal of LIFO (last-in, first-out).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B. of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
Repeal of LIFO (last-in, first-out).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Repeal of LIFO (last-in, first-out).
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Prompt Pay Discount exclusion legislation to ensure more appropriate general payment amount for drugs and biological under Part B of Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Repeal of LIFO (last in, first out).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Repeal of LIFO (last in, first out).
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE